PT-141 (Bremelanotide) Geriatric Dosing: What Adults 65 and Older Need to Know

Why Geriatric Dosing Requires Separate Consideration

Bremelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus to increase sexual desire, and the FDA-approved prescribing information does not specify a separate dose for older adults. That absence of guidance is itself a clinical signal. The RECONNECT trials enrolled premenopausal women, a population that by definition excluded most individuals over 60 [1]. No dedicated pharmacokinetic study in adults 65 and older has been published.

Age-related physiological changes alter how bremelanotide behaves in the body. Glomerular filtration rate (GFR) declines at an estimated rate of 0.7 to 1.0 mL/min/year after age 40, according to longitudinal data from the Baltimore Longitudinal Study of Aging. Because 64.8% of a bremelanotide dose is excreted renally, reduced kidney function can prolong drug exposure and amplify both therapeutic and adverse effects [2]. Hepatic blood flow also decreases by approximately 20 to 40% between ages 25 and 65, per the American Geriatrics Society's pharmacology guidance, potentially affecting first-pass metabolism of concomitant medications even though bremelanotide itself is not heavily hepatically metabolized [3].

The practical reality: prescribers who use bremelanotide off-label in older adults are making individualized risk-benefit decisions without population-level geriatric data to guide them.

The Standard Dose and How It Applies to Older Adults

The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. No more than one dose should be administered in any 24-hour period, and patients should not exceed 8 doses per month [4]. This dosing schedule remains the starting reference point for all adults, including those over 65.

Some clinicians have reported starting geriatric patients on lower compounded doses (0.5 to 1.0 mg) to assess tolerability before advancing to the full 1.75 mg. That approach is not validated in published trials. It follows general geriatric prescribing principles articulated in the American Geriatrics Society Beers Criteria, which recommend starting at the lowest effective dose for medications without geriatric-specific data [5]. The subcutaneous auto-injector device (Vyleesi) delivers a fixed 1.75 mg dose and cannot be titrated downward, so dose reduction requires compounded formulations.

Blood Pressure: The Primary Safety Concern in Older Adults

Bremelanotide causes a transient rise in blood pressure that peaks within one hour of injection. Across the RECONNECT program, mean increases were approximately 6 mmHg systolic and 3 mmHg diastolic, with blood pressure returning to baseline within 12 hours [1]. The FDA label carries a specific warning against use in patients with uncontrolled hypertension or known cardiovascular disease.

This warning takes on greater weight in adults over 65. Approximately 74.5% of U.S. adults aged 60 and older have hypertension, according to NHANES data analyzed by the CDC [6]. A 6 mmHg systolic spike may be clinically insignificant in a healthy 35-year-old. The same spike in a 72-year-old with stiff arterial walls, existing left ventricular hypertrophy, or prior cerebrovascular events carries a different risk profile entirely.

Isolated systolic hypertension, the most common hypertension subtype in older adults, means the arterial system is already operating with reduced compliance. The Framingham Heart Study demonstrated that each 10 mmHg increase in systolic blood pressure above 115 mmHg roughly doubles cardiovascular event risk [7]. For patients already near a systolic threshold of 140 or 150, even a brief 6 mmHg increase could place them in a higher-risk hemodynamic range during the hour following injection.

Clinical recommendation: obtain a baseline blood pressure reading on the day of first use. Patients whose resting systolic exceeds 140 mmHg or who take three or more antihypertensive agents should discuss bremelanotide risks with their cardiologist before proceeding.

Renal Function and Drug Clearance

The kidneys handle nearly two-thirds of bremelanotide elimination. A 70-year-old with a GFR of 55 mL/min (CKD stage 3a, common and often asymptomatic) will clear the drug more slowly than the premenopausal trial participants whose mean GFR likely exceeded 90 mL/min.

The FDA label for Vyleesi does not provide pharmacokinetic data stratified by renal function [4]. No dose adjustment is formally required for mild-to-moderate renal impairment, but this reflects absence of data rather than evidence of safety. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that all renally cleared medications be reassessed when eGFR falls below 60 mL/min [8].

Practical steps for prescribers:

• Order a basic metabolic panel including serum creatinine and calculate eGFR before initiating bremelanotide in any patient over 65
• For eGFR 45 to 59 mL/min, consider extending the minimum dosing interval beyond 24 hours (e.g., no more than one dose per 48 hours)
• For eGFR below 30 mL/min, the risk-benefit ratio likely does not favor bremelanotide use given the complete lack of safety data in severe renal impairment

Cystatin C-based GFR estimation may be more accurate than creatinine-based calculations in older adults with low muscle mass, as noted by the National Kidney Foundation and ASN joint task force [9].

Drug-Drug Interactions in a Polypharmacy Population

Adults aged 65 and older take a median of 4 to 5 prescription medications, per data from the CDC's National Center for Health Statistics [10]. This polypharmacy burden creates interaction risks specific to bremelanotide's pharmacology.

Antihypertensives. The additive blood pressure effects with naltrexone are documented in the Vyleesi label, which warns against concurrent use of bremelanotide with oral naltrexone due to decreased naltrexone efficacy [4]. The blood pressure rise from bremelanotide could also counteract the effects of antihypertensive therapy. Patients on multiple blood pressure medications may find their regimen temporarily less effective in the hour following injection.

PDE5 inhibitors. Many older men using bremelanotide off-label for erectile dysfunction may also take sildenafil, tadalafil, or vardenafil. PDE5 inhibitors lower blood pressure; bremelanotide raises it. The hemodynamic result of combining these agents has not been studied. The theoretical concern is not the opposing effects canceling out but rather unpredictable blood pressure swings in a population with reduced baroreceptor sensitivity. The Endocrine Society's guidelines on testosterone therapy note that cardiovascular safety monitoring is required whenever adding vasoactive agents in older men [11].

Anticoagulants and antiplatelets. No direct pharmacokinetic interaction is expected. The concern is indirect: bremelanotide-induced nausea occurs in 40% of users and vomiting in 5%. For patients on warfarin, oral rivaroxaban, or apixaban, vomiting within 1 to 2 hours of taking an oral anticoagulant can reduce absorption and create a gap in anticoagulation coverage.

SSRIs and SNRIs. Because bremelanotide's mechanism involves central melanocortin signaling rather than serotonergic or dopaminergic pathways, pharmacodynamic interactions with SSRIs are not well characterized. Some clinicians prescribe bremelanotide specifically to counteract SSRI-induced sexual dysfunction. No published data supports or refutes this use in geriatric populations.

Nausea and Fall Risk

Nausea is the most frequently reported adverse event with bremelanotide. In the RECONNECT trials, 40.0% of bremelanotide-treated patients experienced nausea compared to 1.3% on placebo [1]. The nausea typically resolves within 2 hours but can be severe enough to cause vomiting, diaphoresis, and presyncope.

For community-dwelling older adults, these symptoms present a falls hazard. The CDC reports that one in four Americans aged 65 and older falls each year, and falls are the leading cause of injury-related death in this age group [12]. A medication that produces transient nausea, dizziness, and blood pressure changes in a darkened bedroom or bathroom increases this risk.

Practical mitigation strategies:

• Administer the first dose during daytime in a supervised clinical setting
• Instruct patients to remain seated for 30 to 45 minutes after injection until nausea peaks and begins to resolve
• Assess gait stability using the Timed Up and Go (TUG) test at baseline; patients with TUG scores exceeding 12 seconds already carry elevated fall risk per AGS/BGS guidelines [13]
• Consider prescribing ondansetron 4 mg orally 30 minutes before the bremelanotide injection as prophylaxis for patients with prior nausea episodes

Skin Hyperpigmentation and Melanoma Screening

Bremelanotide activates MC1R in addition to MC4R, which stimulates melanogenesis. The Vyleesi label notes focal hyperpigmentation of the face, gingiva, and breasts in some users [4]. While this effect was mild and reversible in younger clinical trial participants, older adults carry a higher baseline risk of melanoma and atypical melanocytic lesions.

The U.S. Preventive Services Task Force has not issued a universal screening recommendation for skin cancer, but the American Cancer Society reports that median age at melanoma diagnosis is 65 [14]. Prescribers should document a baseline skin examination and advise patients to report any new or changing pigmented lesions during bremelanotide use.

Off-Label Use in Older Men with Erectile Dysfunction

Bremelanotide is FDA-approved only for HSDD in premenopausal women. Its use in men for erectile dysfunction or low sexual desire is entirely off-label. Clinical interest exists because bremelanotide works through a central mechanism of action independent of nitric oxide signaling, which theoretically benefits men who do not respond to PDE5 inhibitors.

A small Phase 2b trial published in the Journal of Sexual Medicine demonstrated improvements in erectile function scores with intranasal bremelanotide in men, though the intranasal formulation was abandoned due to blood pressure concerns [15]. The subcutaneous formulation used in Vyleesi has not been studied in a male ED population in a Phase 3 trial.

For older men considering off-label bremelanotide, the same geriatric cautions apply with additional emphasis on cardiovascular screening. The American Urological Association's ED guidelines recommend a cardiovascular risk assessment before initiating any pharmacotherapy for erectile dysfunction in men over 60 [16].

Monitoring Protocol for Geriatric Patients

A structured monitoring approach reduces uncertainty when prescribing bremelanotide to adults 65 and older:

Before the first dose:

• Comprehensive metabolic panel with eGFR calculation (cystatin C preferred)
• Resting blood pressure on two separate occasions
• Medication reconciliation with attention to antihypertensives, naltrexone, PDE5 inhibitors, and anticoagulants
• Baseline skin examination documenting existing pigmented lesions
• Fall risk screening (TUG test or equivalent)
• Assessment for uncontrolled cardiovascular disease, which is a contraindication

At first dose (ideally in-office):

• Blood pressure at 30 and 60 minutes post-injection
• Nausea assessment using a visual analog scale
• Orthostatic vitals before the patient leaves

At 30-day follow-up:

• Blood pressure trends
• Nausea frequency and severity
• Number of doses used (confirm adherence to the 8 doses per month maximum)
• Skin examination for new hyperpigmentation
• Repeat eGFR if baseline was 45 to 59 mL/min

When Bremelanotide May Not Be Appropriate for Older Adults

Certain clinical scenarios should prompt prescribers to avoid bremelanotide in geriatric patients:

• Uncontrolled hypertension (systolic consistently >160 mmHg on maximum medical therapy)
• eGFR <30 mL/min (CKD stage 4 or 5)
• History of stroke or transient ischemic attack within the past 6 months
• Active treatment with naltrexone for alcohol use disorder or opioid dependence
• High fall risk (TUG >20 seconds, history of 2+ falls in the prior year, or current use of 3+ fall-risk-increasing drugs)
• Known melanoma or multiple dysplastic nevi under active dermatologic surveillance

The decision to prescribe bremelanotide in adults 65 and older rests on individualized clinical judgment informed by renal function, cardiovascular status, fall risk, and a realistic discussion of what the drug can and cannot do. For a 68-year-old woman with stable blood pressure, normal kidney function, and distressing HSDD, bremelanotide at 1.75 mg as needed may be a reasonable option with appropriate monitoring. For a 78-year-old man on five medications with CKD stage 3b and a prior TIA, the risk calculus points strongly away from use. Baseline eGFR, resting blood pressure, and a 60-minute post-dose vitals check remain the minimum safety anchors for any geriatric prescribing decision.